Immunopathobiology and therapeutic targets related to cytokines in liver diseases.
Fibrosis
Inflammation
NAFLD
T helper; ALD
Journal
Cellular & molecular immunology
ISSN: 2042-0226
Titre abrégé: Cell Mol Immunol
Pays: China
ID NLM: 101242872
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
09
09
2020
accepted:
15
10
2020
pubmed:
19
11
2020
medline:
28
12
2021
entrez:
18
11
2020
Statut:
ppublish
Résumé
Chronic liver injury with any etiology can progress to fibrosis and the end-stage diseases cirrhosis and hepatocellular carcinoma. The progression of liver disease is controlled by a variety of factors, including liver injury, inflammatory cells, inflammatory mediators, cytokines, and the gut microbiome. In the current review, we discuss recent data on a large number of cytokines that play important roles in regulating liver injury, inflammation, fibrosis, and regeneration, with a focus on interferons and T helper (Th) 1, Th2, Th9, Th17, interleukin (IL)-1 family, IL-6 family, and IL-20 family cytokines. Hepatocytes can also produce certain cytokines (such as IL-7, IL-11, and IL-33), and the functions of these cytokines in the liver are briefly summarized. Several cytokines have great therapeutic potential, and some are currently being tested as therapeutic targets in clinical trials for the treatment of liver diseases, which are also described.
Identifiants
pubmed: 33203939
doi: 10.1038/s41423-020-00580-w
pii: 10.1038/s41423-020-00580-w
pmc: PMC7853124
doi:
Substances chimiques
Cytokines
0
Inflammation Mediators
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
18-37Subventions
Organisme : NIAAA NIH HHS
ID : R01 AA011576
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA026933
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA018663
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA029019
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA017729
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA028550
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA022614
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK101737
Pays : United States
Organisme : NIDDK NIH HHS
ID : R56 DK088837
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK111866
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK099205
Pays : United States
Références
Asrani, S. K., Devarbhavi, H., Eaton, J. & Kamath, P. S. Burden of liver diseases in the world. J. Hepatol. 70, 151–171 (2019).
pubmed: 30266282
Paik, J. M., Golabi, P., Younossi, Y., Mishra, A., Younossi, Z. M. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of nonalcoholic fatty liver disease. Hepatology (2020). in press, https://doi.org/10.1002/hep.31173 .
Crabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L. & Lucey, M. R. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 71, 306–333 (2020).
pubmed: 31314133
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908–922 (2018).
pubmed: 29967350
pmcid: 6553468
Liaskou, E., Hirschfield, G. M. & Gershwin, M. E. Mechanisms of tissue injury in autoimmune liver diseases. Semin. Immunopathol. 36, 553–568 (2014).
pubmed: 25082647
Gao, B., Ahmad, M. F., Nagy, L. E. & Tsukamoto, H. Inflammatory pathways in alcoholic steatohepatitis. J. Hepatol. 70, 249–259 (2019).
pubmed: 30658726
pmcid: 6361545
Koyama, Y. & Brenner, D. A. Liver inflammation and fibrosis. J. Clin. Investig. 127, 55–64 (2017).
pubmed: 28045404
Wree, A., Holtmann, T. M., Inzaugarat, M. E. & Feldstein, A. E. Novel drivers of the inflammatory response in liver injury and fibrosis. Semin. Liver Dis. 39, 275–282 (2019).
pubmed: 31100758
Radaeva, S. et al. Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology 122, 1020–1034 (2002).
pubmed: 11910354
Hermant, P. et al. Human but not mouse hepatocytes respond to interferon-lambda in vivo. PLoS ONE 9, e87906 (2014).
pubmed: 24498220
pmcid: 3909289
Koestner, W. et al. Interferon-beta expression and type I interferon receptor signaling of hepatocytes prevent hepatic necrosis and virus dissemination in Coxsackievirus B3-infected mice. PLoS Pathog. 14, e1007235 (2018).
pubmed: 30075026
pmcid: 6107283
Lercher, A. et al. Type I interferon signaling disrupts the hepatic urea cycle and alters systemic metabolism to suppress T cell function. Immunity 51, 1074–1087 e9 (2019).
pubmed: 31784108
pmcid: 6926485
Eslam, M., Ahlenstiel, G. & George, J. Interferon lambda and liver fibrosis. J. Interferon Cytokine Res. 39, 627–635 (2019).
pubmed: 31013168
Eslam, M. et al. Interferon-lambda rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat. Commun. 6, 6422 (2015).
pubmed: 25740255
pmcid: 4366528
Wei, J. et al. SNX8 mediates IFNgamma-triggered noncanonical signaling pathway and host defense against Listeria monocytogenes. Proc. Natl Acad. Sci. USA 114, 13000–13005 (2017).
pubmed: 29180417
Dunn, G. P., Koebel, C. M. & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6, 836–848 (2006).
pubmed: 17063185
Chen, Y., Hao, X., Sun, R., Wei, H. & Tian, Z. Natural killer cell-derived interferon-gamma promotes hepatocellular carcinoma through the epithelial cell adhesion molecule-epithelial-to-mesenchymal transition axis in hepatitis B virus transgenic mice. Hepatology 69, 1735–1750 (2019).
pubmed: 30329167
Kalathil, S. G., Hutson, A., Barbi, J., Iyer, R. & Thanavala, Y. Augmentation of IFN-gamma+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. JCI Insight 4, e130116 (2019).
pmcid: 6693832
Zeng, Z. et al. Interferon-gamma facilitates hepatic antiviral T cell retention for the maintenance of liver-induced systemic tolerance. J. Exp. Med. 213, 1079–1093 (2016).
pubmed: 27139489
pmcid: 4886358
Wang, H. et al. TNF-alpha/IFN-gamma profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection. J. Hepatol. 72, 45–56 (2020).
pubmed: 31499130
Bae, H. R. et al. Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance. Hepatology 64, 1189–1201 (2016).
pubmed: 27178326
pmcid: 5033675
Ravichandran, G. et al. Interferon-gamma-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice. J. Hepatol. 71, 773–782 (2019).
pubmed: 31173810
Glaser, F. et al. Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis. J. Hepatol. 71, 783–792 (2019).
pubmed: 31207266
Radaeva, S. et al. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130, 435–452 (2006).
pubmed: 16472598
Jeong, W. I., Park, O., Radaeva, S. & Gao, B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 44, 1441–1451 (2006).
pubmed: 17133483
Weng, H., Mertens, P. R., Gressner, A. M. & Dooley, S. IFN-gamma abrogates profibrogenic TGF-beta signaling in liver by targeting expression of inhibitory and receptor Smads. J. Hepatol. 46, 295–303 (2007).
pubmed: 17125875
Gao, B. Cytokines, STATs and liver disease. Cell Mol. Immunol. 2, 92–100 (2005).
pubmed: 16191414
He, X. et al. MicroRNA-351 promotes schistosomiasis-induced hepatic fibrosis by targeting the vitamin D receptor. Proc. Natl Acad. Sci. USA 115, 180–185 (2018).
pubmed: 29255036
Tosello-Trampont, A. C. et al. NKp46(+) natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice. Hepatology 63, 799–812 (2016).
pubmed: 26662852
pmcid: 4764418
Hart, K. M. et al. Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-beta. Sci. Transl. Med. 9, eaal3694 (2017).
pubmed: 28659437
Xiang, X. et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice. J. Hepatol. 72, 736–745 (2020).
pubmed: 31786256
Wallach, D. et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 17, 331–367 (1999).
pubmed: 10358762
Boetticher, N. C. et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 135, 1953–1960 (2008).
pubmed: 18848937
pmcid: 2639749
Su, L. et al. Kupffer cell-derived TNF-alpha promotes hepatocytes to produce CXCL1 and mobilize neutrophils in response to necrotic cells. Cell Death Dis. 9, 323 (2018).
pubmed: 29476069
pmcid: 5833701
Hwang, S. et al. Protective and detrimental roles of p38alpha MAPK in different stages of nonalcoholic fatty liver disease. Hepatology 72, 873–891 (2020).
Hwang, S. et al. Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets. Hepatology 72, 412–429 (2019).
Choi, Y. S. et al. Tumor necrosis factor-producing T-regulatory cells are associated with severe liver injury in patients with acute hepatitis A. Gastroenterology 154, 1047–1060 (2018).
pubmed: 29229400
Li, X. F. et al. Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance. Hepatology 66, 1934–1951 (2017).
pubmed: 28714104
Tan, W. et al. TNF-alpha is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. EBioMedicine 40, 446–456 (2019).
pubmed: 30594557
Tait Wojno, E. D., Hunter, C. A. & Stumhofer, J. S. The immunobiology of the interleukin-12 family: room for discovery. Immunity 50, 851–870 (2019).
pubmed: 30995503
Hou, X. et al. CD205-TLR9-IL-12 axis contributes to CpG-induced oversensitive liver injury in HBsAg transgenic mice by promoting the interaction of NKT cells with Kupffer cells. Cell Mol. Immunol. 14, 675–684 (2017).
pubmed: 27041637
Dias, J. et al. Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. J. Hepatol. 71, 301–312 (2019).
pubmed: 31100314
pmcid: 6642010
Heymann, F. & Tacke, F. Immunology in the liver-from homeostasis to disease. Nat. Rev. Gastroenterol. Hepatol. 13, 88–110 (2016).
pubmed: 26758786
Everts, B. et al. Migratory CD103+ dendritic cells suppress helminth-driven type 2 immunity through constitutive expression of IL-12. J. Exp. Med. 213, 35–51 (2016).
pubmed: 26712805
pmcid: 4710198
Liberal, R. et al. Regulatory T-cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis. Hepatology 66, 1570–1584 (2017).
pubmed: 28597951
pmcid: 5689077
Schwinge, D. et al. Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related to IL-12 signaling. J. Hepatol. 66, 798–805 (2017).
pubmed: 27965154
Busato, D. et al. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Rev. Clin. Pharmacol. 12, 453–470 (2019).
pubmed: 30907177
Liu, Y. et al. Armored inducible expression of IL-12 enhances antitumor activity of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma. J. Immunol. 203, 198–207 (2019).
pubmed: 31142602
Malek, T. R. The biology of interleukin-2. Annu. Rev. Immunol. 26, 453–479 (2008).
pubmed: 18062768
Tan, X. et al. Elevated hepatic CD1d levels coincide with invariant NKT cell defects in chronic hepatitis B virus infection. J. Immunol. 200, 3530–3538 (2018).
pubmed: 29643189
Salimzadeh, L. et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J. Clin. Investig. 128, 4573–4587 (2018).
pubmed: 30084841
Pallett, L. J. et al. IL-2(high) tissue-resident T cells in the human liver: sentinels for hepatotropic infection. J. Exp. Med. 214, 1567–1580 (2017).
pubmed: 28526759
pmcid: 5461007
Wing, K. & Sakaguchi, S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 11, 7–13 (2010).
pubmed: 20016504
Klatzmann, D. & Abbas, A. K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. 15, 283–294 (2015).
pubmed: 25882245
Liberal, R. et al. In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression. Hepatology 62, 863–875 (2015).
pubmed: 25953611
Taubert, R. et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J. Hepatol. 61, 1106–1114 (2014).
pubmed: 24882050
Jeffery, H. C. et al. Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases. Clin. Exp. Immunol. 188, 394–411 (2017).
pubmed: 28176332
pmcid: 5422719
Taylor, A. E. et al. Interleukin 2 promotes hepatic regulatory T cell responses and protects from biliary fibrosis in murine sclerosing cholangitis. Hepatology 68, 1905–1921 (2018).
pubmed: 29698570
pmcid: 6203671
Gu, J. et al. Human CD39(hi) regulatory T cells present stronger stability and function under inflammatory conditions. Cell Mol. Immunol. 14, 521–528 (2017).
pubmed: 27374793
Wills-Karp, M. et al. Interleukin-13: central mediator of allergic asthma. Science 282, 2258–2261 (1998).
pubmed: 9856949
Grunig, G. et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282, 2261–2263 (1998).
pubmed: 9856950
pmcid: 3897229
Bao, K. & Reinhardt, R. L. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. Cytokine 75, 25–37 (2015).
pubmed: 26073683
pmcid: 5118948
McCormick, S. M. & Heller, N. M. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine 75, 38–50 (2015).
pubmed: 26187331
pmcid: 4546937
Ouyang, W. et al. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity 12, 27–37 (2000).
pubmed: 10661403
Ramsay, N. K. & Kersey, J. H. Indications for marrow transplantation in acute lymphoblastic leukemia. Blood 75, 815–818 (1990).
pubmed: 2405919
Zheng, T. et al. IL-13 receptor alpha2 selectively inhibits IL-13-induced responses in the murine lung. J. Immunol. 180, 522–529 (2008).
pubmed: 18097054
Fichtner-Feigl, S., Strober, W., Kawakami, K., Puri, R. K. & Kitani, A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med. 12, 99–106 (2006).
pubmed: 16327802
Gieseck, R. L. 3rd, Wilson, M. S. & Wynn, T. A. Type 2 immunity in tissue repair and fibrosis. Nat. Rev. Immunol. 18, 62–76 (2018).
pubmed: 28853443
Cordero-Espinoza, L. & Huch, M. The balancing act of the liver: tissue regeneration versus fibrosis. J. Clin. Investig 128, 85–96 (2018).
pubmed: 29293095
Pearce, E. J. & MacDonald, A. S. The immunobiology of schistosomiasis. Nat. Rev. Immunol. 2, 499–511 (2002).
pubmed: 12094224
He, X. et al. Recombinant adeno-associated virus-mediated inhibition of microRNA-21 protects mice against the lethal schistosome infection by repressing both IL-13 and transforming growth factor beta 1 pathways. Hepatology 61, 2008–2017 (2015).
pubmed: 25546547
pmcid: 4441614
Gieseck, R. L. 3rd et al. Interleukin-13 activates distinct cellular pathways leading to ductular reaction, steatosis, and fibrosis. Immunity 45, 145–158 (2016).
pubmed: 27421703
pmcid: 4956513
McDaniel, K. et al. Amelioration of ductular reaction by stem cell derived extracellular vesicles in MDR2 knockout mice via lethal-7 microRNA. Hepatology 69, 2562–2578 (2019).
pubmed: 30723922
pmcid: 7015419
Hahn, L. et al. IL-13 as target to reduce cholestasis and dysbiosis in Abcb4 knockout mice. Cells 9, 1949 (2020).
pmcid: 7564366
Walker, J. A. & McKenzie, A. N. J. TH2 cell development and function. Nat. Rev. Immunol. 18, 121–133 (2018).
pubmed: 29082915
Gordon, S. & Martinez, F. O. Alternative activation of macrophages: mechanism and functions. Immunity 32, 593–604 (2010).
pubmed: 20510870
Su, S. et al. miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program. Nat. Commun. 6, 8523 (2015).
pubmed: 26436920
pmcid: 4600756
Wang, M. et al. Role of gp91(phox) in hepatic macrophage programming and alcoholic liver disease. Hepatol. Commun. 1, 765–779 (2017).
pubmed: 29404493
pmcid: 5678917
Goh, Y. P. et al. Eosinophils secrete IL-4 to facilitate liver regeneration. Proc. Natl Acad. Sci. USA 110, 9914–9919 (2013).
pubmed: 23716700
Yeung, O. W. et al. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J. Hepatol. 62, 607–616 (2015).
pubmed: 25450711
Zhu, Y. et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut 68, 1653–1666 (2019).
pubmed: 30902885
Brunner, S. M. et al. Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology 61, 1957–1967 (2015).
pubmed: 25645298
Jin, Z. et al. IL-33 released in the liver inhibits tumor growth via promotion of CD4(+) and CD8(+) T cell responses in hepatocellular carcinoma. J. Immunol. 201, 3770–3779 (2018).
pubmed: 30446569
Yu, S. J. et al. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. J. Hepatol. 70, 449–457 (2019).
pubmed: 30414862
Pelaia, C. et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 10, 1514 (2019).
pubmed: 31920718
pmcid: 6927944
Molfino, N. A., Gossage, D., Kolbeck, R., Parker, J. M. & Geba, G. P. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin. Exp. Allergy 42, 712–737 (2012).
pubmed: 22092535
Pelaia, C. et al. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des. Devel Ther. 11, 3137–3144 (2017).
pubmed: 29133975
pmcid: 5669784
Schwartz, C. et al. Eosinophil-specific deletion of IκBα in mice reveals a critical role of NF-κB-induced Bcl-xL for inhibition of apoptosis. Blood 125, 3896–3904 (2015).
pubmed: 25862560
pmcid: 4473117
Tiegs, G., Hentschel, J. & Wendel, A. A. T cell-dependent experimental liver injury in mice inducible by concanavalin A. J. Clin. Investig. 90, 196–203 (1992).
pubmed: 1634608
Neumann, K. et al. A proinflammatory role of type 2 innate lymphoid cells in murine immune-mediated hepatitis. J. Immunol. 198, 128–137 (2017).
pubmed: 27872212
Liu, Z. X., Govindarajan, S., Okamoto, S. & Dennert, G. Fas- and tumor necrosis factor receptor 1-dependent but not perforin-dependent pathways cause injury in livers infected with an adenovirus construct in mice. Hepatology 31, 665–673 (2000).
pubmed: 10706557
Peng, H. et al. IL-33 contributes to schistosoma japonicum-induced hepatic pathology through induction of M2 macrophages. Sci. Rep. 6, 29844 (2016).
pubmed: 27445267
pmcid: 4956744
Sanches, R. C. O. et al. NLRP6 plays an important role in early hepatic immunopathology caused by Schistosoma mansoni infection. Front. Immunol. 11, 795 (2020).
pubmed: 32431709
pmcid: 7214731
Kaplan, M. H., Hufford, M. M. & Olson, M. R. The development and in vivo function of T helper 9 cells. Nat. Rev. Immunol. 15, 295–307 (2015).
pubmed: 25848755
pmcid: 4445728
Nowak, E. C. et al. IL-9 as a mediator of Th17-driven inflammatory disease. J. Exp. Med. 206, 1653–1660 (2009).
pubmed: 19596803
pmcid: 2722185
Townsend, J. M. et al. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 13, 573–583 (2000).
pubmed: 11070175
Jäger, A., Dardalhon, V., Sobel, R. A., Bettelli, E. & Kuchroo, V. K. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J. Immunol. 183, 7169–7177 (2009).
pubmed: 19890056
pmcid: 2921715
Elyaman, W. et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc. Natl Acad. Sci. USA 106, 12885–12890 (2009).
pubmed: 19433802
Lu, Y. et al. Th9 cells promote antitumor immune responses in vivo. J. Clin. Investig 122, 4160–4171 (2012).
pubmed: 23064366
Clark, R. A. & Schlapbach, C. T(H)9 cells in skin disorders. Semin Immunopathol. 39, 47–54 (2017).
pubmed: 27896634
Koch, S., Sopel, N. & Finotto, S. Th9 and other IL-9-producing cells in allergic asthma. Semin Immunopathol. 39, 55–68 (2017).
pubmed: 27858144
Guo, X., Cen, Y., Wang, J. & Jiang, H. CXCL10-induced IL-9 promotes liver fibrosis via Raf/MEK/ERK signaling pathway. Biomed. Pharmacother. 105, 282–289 (2018).
pubmed: 29860220
Barsoum, R. S., Esmat, G. & El-Baz, T. Human schistosomiasis: clinical perspective: review. J. Adv. Res. 4, 433–444 (2013).
pubmed: 25685450
pmcid: 4293888
Li, L. et al. Characteristics of IL-9 induced by Schistosoma japonicum infection in C57BL/6 mouse liver. Sci. Rep. 7, 2343 (2017).
pubmed: 28539607
pmcid: 5443805
Zhan, T. et al. Interleukin-9 blockage reduces early hepatic granuloma formation and fibrosis during Schistosoma japonicum infection in mice. Immunology 158, 296–303 (2019).
pubmed: 31436861
pmcid: 6856936
Pang, N. et al. TGF-β/Smad signaling pathway positively up-regulates the differentiation of Interleukin-9-producing CD4(+) T cells in human Echinococcus granulosus infection. J. Infect. 76, 406–416 (2018).
pubmed: 29391143
Qin, S. Y. et al. A deleterious role for Th9/IL-9 in hepatic fibrogenesis. Sci. Rep. 6, 18694 (2016).
pubmed: 26728971
pmcid: 4700496
Yu, X. et al. Serum interleukin (IL)-9 and IL-10, but not T-helper 9 (Th9) cells, are associated with survival of patients with acute-on-chronic hepatitis B liver failure. Medicine 95, e3405 (2016).
pubmed: 27100428
pmcid: 4845832
Ali, M. E. et al. Role of T-helper 9 cells in chronic hepatitis C-infected patients. Viruses 10, 341 (2018).
pmcid: 6071239
Schmitt, E. & Bopp, T. Amazing IL-9: revealing a new function for an “old” cytokine. J. Clin. Invest 122, 3857–3859 (2012).
pubmed: 23064368
pmcid: 3484464
Tan, H., Wang, S. & Zhao, L. A tumour-promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways. Clin. Exp. Pharmacol. Physiol. 44, 213–221 (2017).
pubmed: 27797409
Meng, F. et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 143, 765–776 (2012).
pubmed: 22687286
pmcid: 3635475
Kolls, J. K. & Linden, A. Interleukin-17 family members and inflammation. Immunity 21, 467–476 (2004).
pubmed: 15485625
Iwakura, Y., Ishigame, H., Saijo, S. & Nakae, S. Functional specialization of interleukin-17 family members. Immunity 34, 149–162 (2011).
pubmed: 21349428
Gaffen, S. L. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 9, 556–567 (2009).
pubmed: 19575028
pmcid: 2821718
Lemmers, A. et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 49, 646–657 (2009).
pubmed: 19177575
Lafdil, F., Miller, A. M., Ki, S. H. & Gao, B. Th17 cells and their associated cytokines in liver diseases. Cell Mol. Immunol. 7, 250–254 (2010).
pubmed: 20305686
pmcid: 3732654
Cua, D. J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744–748 (2003).
pubmed: 12610626
Diveu, C. et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J. Immunol. 182, 5748–5756 (2009).
pubmed: 19380822
Hall, A. O., Silver, J. S. & Hunter, C. A. The immunobiology of IL-27. Adv. Immunol. 115, 1–44 (2012).
pubmed: 22608254
Liu, Y., Munker, S., Mullenbach, R. & Weng, H. L. IL-13 signaling in liver fibrogenesis. Front Immunol. 3, 116 (2012).
pubmed: 22593760
pmcid: 3349963
Kleinschek, M. A. et al. IL-25 regulates Th17 function in autoimmune inflammation. J. Exp. Med 204, 161–170 (2007).
pubmed: 17200411
pmcid: 2118427
Ivanov, I. I. et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126, 1121–1133 (2006).
pubmed: 16990136
Yao, Z. et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3, 811–821 (1995).
pubmed: 8777726
Andoh, A. et al. IL-17 selectively down-regulates TNF-alpha-induced RANTES gene expression in human colonic subepithelial myofibroblasts. J. Immunol. 169, 1683–1687 (2002).
pubmed: 12165487
Moore, E. E. et al. Expression of IL-17B in neurons and evaluation of its possible role in the chromosome 5q-linked form of Charcot-Marie-Tooth disease. Neuromuscul. Disord. 12, 141–150 (2002).
pubmed: 11738356
Yamaguchi, Y. et al. IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. J. Immunol. 179, 7128–7136 (2007).
pubmed: 17982105
Starnes, T., Broxmeyer, H. E., Robertson, M. J. & Hromas, R. Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J. Immunol. 169, 642–646 (2002).
pubmed: 12097364
Seelige, R., Washington, A. Jr & Bui, J. D. The ancient cytokine IL-17D is regulated by Nrf2 and mediates tumor and virus surveillance. Cytokine 91, 10–12 (2017).
pubmed: 27940089
Takatori, H. et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J. Exp. Med 206, 35–41 (2009).
pubmed: 19114665
pmcid: 2626689
Lee, J. et al. IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J. Biol. Chem. 276, 1660–1664 (2001).
pubmed: 11058597
Rickel, E. A. et al. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J. Immunol. 181, 4299–4310 (2008).
pubmed: 18768888
Liu, C. et al. A CC’ loop decoy peptide blocks the interaction between Act1 and IL-17RA to attenuate IL-17- and IL-25-induced inflammation. Sci. Signal 4, ra72 (2011).
pubmed: 22045852
pmcid: 3282585
Giles, D. A. et al. Regulation of inflammation by IL-17A and IL-17F modulates non-alcoholic fatty liver disease pathogenesis. PLoS ONE 11, e0149783 (2016).
pubmed: 26895034
pmcid: 4760740
von Vietinghoff, S. & Ley, K. IL-17A controls IL-17F production and maintains blood neutrophil counts in mice. J. Immunol. 183, 865–873 (2009).
Ma, H. Y. et al. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. J. Hepatol. 72, 946–959 (2020).
pubmed: 31899206
Xu, J. et al. Blockade of IL-17 signaling reverses alcohol-induced liver injury and excessive alcohol drinking in mice. JCI Insight 5, e131277 (2020).
pmcid: 7098802
Ortiz, M. L. et al. Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells. J. Exp. Med. 212, 351–367 (2015).
pubmed: 25667306
pmcid: 4354367
Gomes, A. L. et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell 30, 161–175 (2016).
pubmed: 27411590
Giles, D. A. et al. Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling. Nat. Med. 23, 829–838 (2017).
pubmed: 28604704
pmcid: 5596511
Seo, W. et al. Exosome-mediated activation of toll-like receptor 3 in stellate cells stimulates interleukin-17 production by gammadelta T cells in liver fibrosis. Hepatology 64, 616–631 (2016).
pubmed: 27178735
Lee, J. H. et al. Mitochondrial double-stranded RNA in exosome promotes interleukin-17 production through toll-like receptor 3 in alcohol-associated liver injury. Hepatology 72, 609–625 (2020).
pubmed: 31849082
Kim, J. Y. et al. ER stress drives lipogenesis and steatohepatitis via caspase-2 activation of S1P. Cell 175, 133–145 e15 (2018).
pubmed: 30220454
pmcid: 6159928
Ikonen, E. Cellular cholesterol trafficking and compartmentalization. Nat. Rev. Mol. Cell Biol. 9, 125–138 (2008).
pubmed: 18216769
Osborne, T. F. & Espenshade, P. J. Evolutionary conservation and adaptation in the mechanism that regulates SREBP action: what a long, strange tRIP it’s been. Genes Dev. 23, 2578–2591 (2009).
pubmed: 19933148
pmcid: 2779761
Fitzky, B. U. et al. 7-Dehydrocholesterol-dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/RSH syndrome. J. Clin. Investig. 108, 905–915 (2001).
pubmed: 11560960
Yu, H. et al. Selective reconstitution of liver cholesterol biosynthesis promotes lung maturation but does not prevent neonatal lethality in Dhcr7 null mice. BMC Dev. Biol. 7, 27 (2007).
pubmed: 17408495
pmcid: 1855921
Yu, H., Wessels, A., Tint, G. S. & Patel, S. B. Partial rescue of neonatal lethality of Dhcr7 null mice by a nestin promoter-driven DHCR7 transgene expression. Brain Res. Dev. Brain Res. 156, 46–60 (2005).
pubmed: 15862627
Boland, M. R. & Tatonetti, N. P. Investigation of 7-dehydrocholesterol reductase pathway to elucidate off-target prenatal effects of pharmaceuticals: a systematic review. Pharmacogenomics J. 16, 411–429 (2016).
pubmed: 27401223
pmcid: 5028238
Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693–1700 (2012).
pubmed: 22595313
pmcid: 4902107
Solt, L. A. et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 472, 491–494 (2011).
pubmed: 21499262
pmcid: 3148894
Ma, H. Y. et al. The role of IL-17 signaling in regulation of the liver-brain axis and intestinal permeability in alcoholic liver disease. Curr. Pathobiol. Rep. 4, 27–35 (2016).
pubmed: 27239399
pmcid: 4878828
Pascual, M., Balino, P., Aragon, C. M. & Guerri, C. Cytokines and chemokines as biomarkers of ethanol-induced neuroinflammation and anxiety-related behavior: role of TLR4 and TLR2. Neuropharmacology 89, 352–359 (2015).
pubmed: 25446779
Chan, A. H. & Schroder, K. Inflammasome signaling and regulation of interleukin-1 family cytokines. J. Exp. Med. 217, e20190314 (2020).
pubmed: 31611248
Mantovani, A., Dinarello, C. A., Molgora, M. & Garlanda, C. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity 50, 778–795 (2019).
pubmed: 30995499
pmcid: 7174020
Negash, A. A. et al. IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog. 9, e1003330 (2013).
pubmed: 23633957
pmcid: 3635973
Dinarello, C. A. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol. Rev. 281, 8–27 (2018).
pubmed: 29247995
pmcid: 5756628
Tilg, H., Moschen, A. R. & Szabo, G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 64, 955–965 (2016).
pubmed: 26773297
Tsutsui, H., Cai, X. & Hayashi, S. Interleukin-1 family cytokines in liver diseases. Mediators Inflamm. 2015, 630265 (2015).
pubmed: 26549942
pmcid: 4624893
Kamari, Y. et al. Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J. Hepatol. 55, 1086–1094 (2011).
pubmed: 21354232
pmcid: 3210940
Almog, T. et al. Interleukin-1α deficiency reduces adiposity, glucose intolerance and hepatic de-novo lipogenesis in diet-induced obese mice. BMJ Open Diabetes Res. Care 7, e000650 (2019).
pubmed: 31749969
pmcid: 6827792
Olteanu, S. et al. Lack of interleukin-1α in Kupffer cells attenuates liver inflammation and expression of inflammatory cytokines in hypercholesterolaemic mice. Dig. Liver Dis. 46, 433–439 (2014).
pubmed: 24582082
Pan, J. et al. Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release. Cell Immunol. 332, 111–120 (2018).
pubmed: 30103942
Mirea, A. M. et al. Mice Deficient in the IL-1β activation genes Prtn3, Elane, and Casp1 are protected against the development of obesity-induced NAFLD. Inflammation 43, 1054–1064 (2020).
pubmed: 32002713
pmcid: 7280336
Cazanave, S. et al. The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. Sci. Rep. 7, 17193 (2017).
pubmed: 29222421
pmcid: 5722878
Xu, B. et al. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. J. Hepatol. 68, 773–782 (2018).
pubmed: 29273476
Palomera, L. F. et al. Serum levels of interleukin-1 beta associate better with severity of simple steatosis than liver function tests in morbidly obese patients. J. Res. Med. Sci. 23, 93 (2018).
pubmed: 30505331
pmcid: 6225445
Yamanishi, K. et al. Interleukin-18-deficient mice develop dyslipidemia resulting in nonalcoholic fatty liver disease and steatohepatitis. Transl. Res. 173, 101–114.e7 (2016).
pubmed: 27063959
Murphy, A. J. et al. IL-18 production from the NLRP1 inflammasome prevents obesity and metabolic syndrome. Cell Metab. 23, 155–164 (2016).
pubmed: 26603191
Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179–185 (2012).
pubmed: 22297845
pmcid: 3276682
Flisiak-Jackiewicz, M. et al. Predictive role of interleukin-18 in liver steatosis in obese children. Can. J. Gastroenterol. Hepatol. 2018, 3870454 (2018).
pubmed: 29854715
pmcid: 5944203
Yasuda, K., Nakanishi, K. & Tsutsui, H. Interleukin-18 in health and disease. Int. J. Mol. Sci. 20, 649 (2019).
McKie, E. A. et al. A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus. PLoS ONE 11, e0150018 (2016).
pubmed: 26930607
pmcid: 4773233
Mridha, A. R. et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. 66, 1037–1046 (2017).
pubmed: 28167322
pmcid: 6536116
Cai, C. et al. NLRP3 deletion inhibits the non-alcoholic steatohepatitis development and inflammation in Kupffer cells induced by palmitic acid. Inflammation 40, 1875–1883 (2017).
pubmed: 28730512
Yang, G., Lee, H. E. & Lee, J. Y. A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet. Sci. Rep. 6, 24399 (2016).
pubmed: 27075683
pmcid: 4830938
Larsen, C. M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med 356, 1517–1526 (2007).
pubmed: 17429083
Everett, B. M. et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J. Am. Coll. Cardiol. 71, 2392–2401 (2018).
pubmed: 29544870
Vasseur, P. et al. Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis. Oncotarget 8, 48563–48574 (2017).
pubmed: 28611297
pmcid: 5564708
Gao, Y. et al. IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis. Oncotarget 7, 33649–33661 (2016).
pubmed: 27172901
pmcid: 5085109
Giannoudaki, E. et al. Interleukin-36 cytokines alter the intestinal microbiome and can protect against obesity and metabolic dysfunction. Nat. Commun. 10, 4003 (2019).
pubmed: 31488830
pmcid: 6728358
Ballak, D. B. et al. IL-37 protects against obesity-induced inflammation and insulin resistance. Nat. Commun. 5, 4711 (2014).
pubmed: 25182023
Petrasek, J. et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J. Clin. Investig. 122, 3476–3489 (2012).
pubmed: 22945633
Petrasek, J. et al. Metabolic danger signals, uric acid and ATP, mediate inflammatory cross-talk between hepatocytes and immune cells in alcoholic liver disease. J. Leukoc. Biol. 98, 249–256 (2015).
pubmed: 25934928
pmcid: 4501673
Voican, C. S. et al. Alcohol withdrawal alleviates adipose tissue inflammation in patients with alcoholic liver disease. Liver Int. 35, 967–978 (2015).
pubmed: 24766056
Cui, K. et al. Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1β in mice. J. Hepatol. 62, 1311–1318 (2015).
pubmed: 25582105
Gyongyosi, B. et al. Alcohol-induced IL-17A production in Paneth cells amplifies endoplasmic reticulum stress, apoptosis, and inflammasome-IL-18 activation in the proximal small intestine in mice. Mucosal Immunol. 12, 930–944 (2019).
pubmed: 31105269
pmcid: 6599481
Khanova, E. et al. Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients. Hepatology 67, 1737–1753 (2018).
pubmed: 29108122
pmcid: 5906140
Iracheta-Vellve, A. et al. Interleukin-1 inhibition facilitates recovery from liver injury and promotes regeneration of hepatocytes in alcoholic hepatitis in mice. Liver Int. 37, 968–973 (2017).
pubmed: 28345165
pmcid: 5479767
NIH U.S. National Library of Medicine. ClinicalTrials.gov. Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis. https://clinicaltrials.gov/ct2/show/NCT01809132 .
McHedlidze, T. et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 39, 357–371 (2013).
pubmed: 23954132
pmcid: 4172965
Marvie, P. et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J. Cell Mol. Med. 14, 1726–1739 (2010).
pubmed: 19508382
Sun, Z. et al. Plasma levels of soluble ST2, but not IL-33, correlate with the severity of alcoholic liver disease. J. Cell Mol. Med. 23, 887–897 (2019).
pubmed: 30478965
Artru, F. et al. IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis. J. Hepatol. 72, 1052–1061 (2020).
pubmed: 31953139
Grabherr, F. et al. Ethanol-mediated suppression of IL-37 licenses alcoholic liver disease. Liver Int 38, 1095–1101 (2018).
pubmed: 29193575
Gieling, R. G., Wallace, K. & Han, Y. P. Interleukin-1 participates in the progression from liver injury to fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G1324–G1331 (2009).
pubmed: 19342509
pmcid: 2697947
Wree, A. et al. NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice. Hepatology 67, 736–749 (2018).
pubmed: 28902427
Meier, R. P. H. et al. Interleukin-1 receptor antagonist modulates liver inflammation and fibrosis in mice in a model-dependent manner. Int J. Mol. Sci. 20, 1295 (2019).
pmcid: 6471711
Monteiro, S. et al. Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. Gut (2020). in press, https://doi.org/10.1136/gutjnl-2019-320170 .
Kotsiou, O. S., Gourgoulianis, K. I. & Zarogiannis, S. G. IL-33/ST2 axis in organ fibrosis. Front Immunol. 9, 2432 (2018).
pubmed: 30405626
pmcid: 6207585
Tan, Z. et al. Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells. Cell Mol. Immunol. 15, 388–398 (2018).
pubmed: 28194023
Sultan, M. et al. Interleukin-1α and Interleukin-1β play a central role in the pathogenesis of fulminant hepatic failure in mice. PLoS ONE 12, e0184084 (2017).
pubmed: 28953903
pmcid: 5617151
Gehrke, N. et al. Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation. J. Hepatol. 68, 986–995 (2018).
pubmed: 29366909
Zhang, C. et al. Macrophage-derived IL-1α promotes sterile inflammation in a mouse model of acetaminophen hepatotoxicity. Cell Mol. Immunol. 15, 973–982 (2018).
pubmed: 28504245
Bachmann, M., Pfeilschifter, J. & Mühl, H. A prominent role of interleukin-18 in acetaminophen-induced liver injury advocates its blockage for therapy of hepatic necroinflammation. Front. Immunol. 9, 161 (2018).
pubmed: 29472923
pmcid: 5809456
Castillo-Dela Cruz, P. et al. Intestinal IL-17R signaling constrains IL-18-driven liver inflammation by the regulation of microbiome-derived products. Cell Rep. 29, 2270–2283.e7 (2019).
pubmed: 31747600
Antunes, M. M. et al. IL-33 signalling in liver immune cells enhances drug-induced liver injury and inflammation. Inflamm. Res. 67, 77–88 (2018).
pubmed: 29032512
Yazdani, H. O. et al. IL-33 exacerbates liver sterile inflammation by amplifying neutrophil extracellular trap formation. J. Hepatol. 68, 130–139 (2018).
Scheiermann, P. et al. Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury. Sci. Rep. 5, 8521 (2015).
pubmed: 25687687
pmcid: 4330543
Feng, X. X. et al. IL-37 suppresses the sustained hepatic IFN-γ/TNF-α production and T cell-dependent liver injury. Int Immunopharmacol. 69, 184–193 (2019).
pubmed: 30735937
Lin, C. I., Tsao, C. C. & Chuang, Y. H. IL-37 increases liver inflammation in Con A-induced hepatitis by increasing IFN-γ secretion of infiltrated NK Cells. J. Immunol. 204, 238.12 (2020).
Fazel Modares, N. et al. IL-6 trans-signaling controls liver regeneration after partial hepatectomy. Hepatology 70, 2075–2091 (2019).
pubmed: 31100194
Lokau, J. et al. Proteolytic cleavage governs interleukin-11 trans-signaling. Cell Rep. 14, 1761–1773 (2016).
pubmed: 26876177
Jones, S. A., Scheller, J. & Rose-John, S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Investig. 121, 3375–3383 (2011).
pubmed: 21881215
Norris, C. A. et al. Synthesis of IL-6 by hepatocytes is a normal response to common hepatic stimuli. PLoS ONE 9, e96053 (2014).
pubmed: 24763697
pmcid: 3999098
Schmidt-Arras, D. & Rose-John, S. IL-6 pathway in the liver: from physiopathology to therapy. J. Hepatol. 64, 1403–1415 (2016).
pubmed: 26867490
Gao, R. Y. et al. Hypoxia-inducible factor-2alpha reprograms liver macrophages to protect against acute liver injury through the production of interleukin-6. Hepatology 71, 2105–2117 (2020).
pubmed: 31529728
Zhang, X. et al. Interleukin-6 is an important mediator for mitochondrial DNA repair after alcoholic liver injury in mice. Hepatology 52, 2137–2147 (2010).
pubmed: 20931558
pmcid: 2991528
Miller, A. M. et al. Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology 54, 846–856 (2011).
pubmed: 21725996
pmcid: 3197882
Mas, E. et al. IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS One 4, e7929 (2009).
pubmed: 19936233
pmcid: 2775411
Xu, M. J. et al. Liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3. Hepatology 61, 692–702 (2015).
pubmed: 25234944
pmcid: 4303493
Aleksandrova, K. et al. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology 60, 858–871 (2014).
pubmed: 24443059
pmcid: 4231978
Wan, S. et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology 147, 1393–1404 (2014).
pubmed: 25181692
pmcid: 4253315
Bergmann, J. et al. IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice. Hepatology 65, 89–103 (2017).
pubmed: 27770462
Isorce, N. et al. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus. Antivir. Res. 130, 36–45 (2016).
pubmed: 26971407
Faure-Dupuy, S. et al. Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection. J. Hepatol. 71, 1086–1098 (2019).
pubmed: 31349000
Lan, T., Chang, L., Wu, L. & Yuan, Y. F. IL-6 plays a crucial role in HBV infection. J. Clin. Transl. Hepatol. 3, 271–276 (2015).
pubmed: 26807383
pmcid: 4721895
Cao, Y. et al. IL-27, a cytokine, and IFN-lambda1, a type III IFN, are coordinated to regulate virus replication through type I IFN. J. Immunol. 192, 691–703 (2014).
pubmed: 24337382
Negash, A. A., Olson, R. M., Griffin, S. & Gale, M. Jr Modulation of calcium signaling pathway by hepatitis C virus core protein stimulates NLRP3 inflammasome activation. PLoS Pathog. 15, e1007593 (2019).
pubmed: 30811485
pmcid: 6392285
Larrea, E. et al. Characterization of the CD40L/Oncostatin M/Oncostatin M receptor axis as an antiviral and immunostimulatory system disrupted in chronic HCV infection. J. Hepatol. 60, 482–489 (2014).
pubmed: 24418171
Yu, J., Feng, Z., Tan, L., Pu, L. & Kong, L. Interleukin-11 protects mouse liver from warm ischemia/reperfusion (WI/Rp) injury. Clin. Res Hepatol. Gastroenterol. 40, 562–570 (2016).
pubmed: 27016892
Widjaja, A. A. et al. Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis. Gastroenterology 157, 777–792 e14 (2019).
pubmed: 31078624
Foglia, B. et al. Oncostatin M, A profibrogenic mediator overexpressed in non-alcoholic fatty liver disease, stimulates migration of hepatic myofibroblasts. Cells 9, 28 (2019).
pmcid: 7017087
Matsuda, M. et al. Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice. Hepatology 67, 296–312 (2018).
pubmed: 28779552
Cui, M. X. et al. Alleviative effect of ciliary neurotrophic factor analogue on high fat-induced hepatic steatosis is partially independent of the central regulation. Clin. Exp. Pharmacol. Physiol. 44, 395–402 (2017).
pubmed: 27973757
Nonogaki, K. et al. LIF and CNTF, which share the gp130 transduction system, stimulate hepatic lipid metabolism in rats. Am. J. Physiol. 271, E521–E528 (1996).
pubmed: 8843746
Guillot, A. et al. Interleukins-17 and 27 promote liver regeneration by sequentially inducing progenitor cell expansion and differentiation. Hepatol. Commun. 2, 329–343 (2018).
pubmed: 29507906
pmcid: 5831061
Lopez-Yoldi, M., Moreno-Aliaga, M. J. & Bustos, M. Cardiotrophin-1: a multifaceted cytokine. Cytokine Growth Factor Rev. 26, 523–532 (2015).
pubmed: 26188636
Dudakov, J. A., Hanash, A. M. & van den Brink, M. R. Interleukin-22: immunobiology and pathology. Annu Rev. Immunol. 33, 747–785 (2015).
pubmed: 25706098
pmcid: 4407497
Sabat, R., Ouyang, W. & Wolk, K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat. Rev. Drug Disco. 13, 21–38 (2014).
Rutz, S., Eidenschenk, C. & Ouyang, W. IL-22, not simply a Th17 cytokine. Immunol. Rev. 252, 116–132 (2013).
pubmed: 23405899
Sabat, R. IL-10 family of cytokines. Cytokine Growth Factor Rev. 21, 315–324 (2010).
pubmed: 21112807
Radaeva, S., Sun, R., Pan, H. N., Hong, F. & Gao, B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39, 1332–1342 (2004).
pubmed: 15122762
Feng, D. et al. Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology 143, 188–98 e7 (2012).
pubmed: 22484119
pmcid: 3384505
Kong, X. et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 56, 1150–1159 (2012).
pubmed: 22473749
pmcid: 3394879
Lejeune, D. et al. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J. Biol. Chem. 277, 33676–33682 (2002).
pubmed: 12087100
Zheng, Y. et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 14, 282–289 (2008).
pubmed: 18264109
Zheng, M. et al. Therapeutic role of interleukin 22 in experimental intra-abdominal Klebsiella pneumoniae infection in mice. Infect. Immun. 84, 782–789 (2016).
pubmed: 26729763
pmcid: 4771339
Liang, S. C. et al. IL-22 induces an acute-phase response. J. Immunol. 185, 5531–5538 (2010).
pubmed: 20870942
Xing, W. W. et al. Hepatoprotective effects of IL-22 on fulminant hepatic failure induced by d-galactosamine and lipopolysaccharide in mice. Cytokine 56, 174–179 (2011).
pubmed: 21843953
Park, O. et al. In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology 54, 252–261 (2011).
pubmed: 21465510
pmcid: 3125432
Ashour, T. H. Therapy with interleukin-22 alleviates hepatic injury and hemostasis dysregulation in rat model of acute liver failure. Adv. Hematol. 2014, 705290 (2014).
pubmed: 24799907
pmcid: 3988755
Wahl, C., Wegenka, U. M., Leithauser, F., Schirmbeck, R. & Reimann, J. IL-22-dependent attenuation of T cell-dependent (ConA) hepatitis in herpes virus entry mediator deficiency. J. Immunol. 182, 4521–4528 (2009).
pubmed: 19342625
Abe, H. et al. Aryl hydrocarbon receptor plays protective roles in ConA-induced hepatic injury by both suppressing IFN-gamma expression and inducing IL-22. Int Immunol. 26, 129–137 (2014).
pubmed: 24150244
Zenewicz, L. A. et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 27, 647–659 (2007).
pubmed: 17919941
pmcid: 2149911
Scheiermann, P. et al. Application of interleukin-22 mediates protection in experimental acetaminophen-induced acute liver injury. Am. J. Pathol. 182, 1107–1113 (2013).
pubmed: 23375450
Feng, D. et al. Acute and chronic effects of IL-22 on acetaminophen-induced liver injury. J. Immunol. 193, 2512–2518 (2014).
pubmed: 25063867
pmcid: 4135042
Pan, H., Hong, F., Radaeva, S. & Gao, B. Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol. Immunol. 1, 43–49 (2004).
pubmed: 16212920
Mo, R. et al. Enhanced autophagy contributes to protective effects of IL-22 against acetaminophen-induced liver injury. Theranostics 8, 4170–4180 (2018).
pubmed: 30128045
pmcid: 6096391
Lai, R. et al. Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury. J. Hepatol. 63, 148–155 (2015).
pubmed: 25681556
Ki, S. H. et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology 52, 1291–1300 (2010).
pubmed: 20842630
pmcid: 2947578
Meng, F. et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 143, 765–776 e3 (2012).
pubmed: 22687286
pmcid: 3635475
Hu, B. L. et al. Interleukin-22 ameliorates liver fibrosis through miR-200a/beta-catenin. Sci. Rep. 6, 36436 (2016).
pubmed: 27819314
pmcid: 5098253
Sertorio, M. et al. IL-22 and IL-22 binding protein (IL-22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections. Hepatology 61, 1321–1331 (2015).
pubmed: 25476703
Fabre, T. et al. Type 3 cytokines IL-17A and IL-22 drive TGF-beta-dependent liver fibrosis. Sci Immunol. 3 (2018).
Wu, L. Y. et al. Up-regulation of interleukin-22 mediates liver fibrosis via activating hepatic stellate cells in patients with hepatitis C. Clin. Immunol. 158, 77–87 (2015).
pubmed: 25771172
Brand, S. et al. IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G1019–G1028 (2007).
pubmed: 17204547
Zhou, H. et al. Enhanced regeneration and hepatoprotective effects of interleukin 22 fusion protein on a predamaged liver undergoing partial hepatectomy. J. Immunol. Res. 2018, 5241526 (2018).
pubmed: 30515423
pmcid: 6234454
Mo, R. et al. Persistently elevated circulating Th22 reversely correlates with prognosis in HBV-related acute-on-chronic liver failure. J. Gastroenterol. Hepatol. 32, 677–686 (2017).
pubmed: 27548078
Schwarzkopf, K. et al. IL-22 and IL-22-binding protein are associated with development of and mortality from acute-on-chronic liver failure. Hepatol. Commun. 3, 392–405 (2019).
pubmed: 30859151
pmcid: 6396350
Yang, L. et al. Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. J. Hepatol. 53, 339–347 (2010).
pubmed: 20452699
Zhang, Y. et al. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology 141, 1897–1906 (2011).
pubmed: 21708106
pmcid: 3199295
Foster, R. G., Golden-Mason, L., Rutebemberwa, A. & Rosen, H. R. Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. Dig. Dis. Sci. 57, 381–389 (2012).
pubmed: 22183819
Zhang, J. Y. et al. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 51, 81–91 (2010).
pubmed: 19842207
Chang, Q. et al. Th17 cells are increased with severity of liver inflammation in patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 27, 273–278 (2012).
pubmed: 21592230
Zhao, J. et al. Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology 59, 1331–1342 (2014).
pubmed: 24677193
pmcid: 3970185
Dambacher, J. et al. The role of interleukin-22 in hepatitis C virus infection. Cytokine 41, 209–216 (2008).
pubmed: 18191408
Jiang, R. et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 54, 900–909 (2011).
pubmed: 21674558
Shi, J. et al. Interleukin 22 is related to development and poor prognosis of hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol. (2020). in press, https://doi.org/10.1016/j.clinre.2020.01.009 .
Waidmann, O. et al. Interleukin-22 serum levels are a negative prognostic indicator in patients with hepatocellular carcinoma. Hepatology 59, 1207 (2014).
pubmed: 23729376
Tang, K. Y. et al. Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects. Cell Mol. Immunol. 16, 473–482 (2019).
pubmed: 29670279
Rothenberg, M. E. et al. Randomized Phase I healthy volunteer study of UTTR1147A (IL-22Fc): a potential therapy for epithelial injury. Clin. Pharmacol. Ther. 105, 177–189 (2019).
pubmed: 29952004
Arab, J. P. et al. An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis. Hepatology 72, 441–453 (2019).
Xiang, X., Hwang, S., Feng, D., Shah, V. H. & Gao, B. Interleukin-22 in alcoholic hepatitis and beyond. Hepatol. Int 14, 667–676 (2020).
pubmed: 32892258
Wolk, K., Kunz, S., Asadullah, K. & Sabat, R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J. Immunol. 168, 5397–5402 (2002).
pubmed: 12023331
Wegenka, U. M., Dikopoulos, N., Reimann, J., Adler, G. & Wahl, C. The murine liver is a potential target organ for IL-19, IL-20 and IL-24: Type I interferons and LPS regulate the expression of IL-20R2. J. Hepatol. 46, 257–265 (2007).
pubmed: 17069926
Hsu, Y. H. et al. Interleukin-19 mediates tissue damage in murine ischemic acute kidney injury. PLoS ONE 8, e56028 (2013).
pubmed: 23468852
pmcid: 3582636
Blumberg, H. et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104, 9–19 (2001).
pubmed: 11163236
Caparros, E. & Frances, R. The interleukin-20 cytokine family in liver disease. Front. Immunol. 9, 1155 (2018).
pubmed: 29892294
pmcid: 5985367
Chiu, Y. S., Wei, C. C., Lin, Y. J., Hsu, Y. H. & Chang, M. S. IL-20 and IL-20R1 antibodies protect against liver fibrosis. Hepatology 60, 1003–1014 (2014).
pubmed: 24763901
Ding, W. Z. et al. Anti-IL-20 monoclonal antibody suppresses hepatocellular carcinoma progression. Oncol. Lett. 16, 6156–6162 (2018).
pubmed: 30333881
pmcid: 6176420
Chiu, Y. S. et al. Anti-IL-20 monoclonal antibody inhibited tumor growth in hepatocellular carcinoma. Sci. Rep. 7, 17609 (2017).
pubmed: 29242565
pmcid: 5730582
Menezes, M. E. et al. MDA-7/IL-24: multifunctional cancer killing cytokine. Adv. Exp. Med Biol. 818, 127–153 (2014).
pubmed: 25001534
pmcid: 4633013
Chen, W. Y. et al. IL-24 inhibits the growth of hepatoma cells in vivo. Genes Immun. 6, 493–499 (2005).
pubmed: 15959534
Wang, C. J. et al. Interferon-alpha enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma. Mol. Cancer 11, 31 (2012).
pubmed: 22569271
pmcid: 3697897
Liu, X. et al. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL. Cancer Gene Ther. 19, 49–57 (2012).
pubmed: 21979578
Tong, A. W. et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol. Ther. 11, 160–172 (2005).
pubmed: 15585417
Cunningham, C. C. et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol. Ther. 11, 149–159 (2005).
pubmed: 15585416
Fisher, P. B. et al. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol. Ther. 2, S23–S37 (2003).
pubmed: 14508078
Wang, J. et al. Intracellular XBP1-IL-24 axis dismantles cytotoxic unfolded protein response in the liver. Cell Death Dis. 11, 17 (2020).
pubmed: 31907348
pmcid: 6944701
Knappe, A., Hor, S., Wittmann, S. & Fickenscher, H. Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J. Virol. 74, 3881–3887 (2000).
pubmed: 10729163
pmcid: 111897
Hor, S. et al. The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains. J. Biol. Chem. 279, 33343–33351 (2004).
pubmed: 15178681
Miot, C. et al. IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells. Gut 64, 1466–1475 (2015).
pubmed: 25183206
Xi, Z. F. et al. Expression of IL-26 predicts prognosis of patients with hepatocellular carcinoma after surgical resection. Hepatobiliary Pancreat. Dis. Int 18, 242–248 (2019).
pubmed: 30956053
Hu, Z. et al. miRNA-132-3p inhibits osteoblast differentiation by targeting Ep300 in simulated microgravity. Sci. Rep. 5, 18655 (2015).
pubmed: 26686902
pmcid: 4685444
Schmitz, J. et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479–490 (2005).
pubmed: 16286016
Arshad, M. I. et al. TRAIL but not FasL and TNFalpha, regulates IL-33 expression in murine hepatocytes during acute hepatitis. Hepatology 56, 2353–2362 (2012).
pubmed: 22961755
von Freeden-Jeffry, U. et al. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J. Exp. Med. 181, 1519–1526 (1995).
Sawa, Y. et al. Hepatic interleukin-7 expression regulates T cell responses. Immunity 30, 447–457 (2009).
pubmed: 19285437
Liang, B. et al. Role of hepatocyte-derived IL-7 in maintenance of intrahepatic NKT cells and T cells and development of B cells in fetal liver. J. Immunol. 189, 4444–4450 (2012).
pubmed: 23018454
Nishina, T. et al. Interleukin-11 links oxidative stress and compensatory proliferation. Sci. Signal 5, ra5 (2012).
pubmed: 22253262